Development and characterization of PLGA nanoparticles containing antibiotics

Gaspar, Lívia Maria do Amorim Costa; Dórea, Afonso Celso Silva; Droppa-Almeida, Daniela; Silva, Isabelle Souza de Mélo; Montoro, Fabiano Emmanuel; Alves, Lumar Lucena; Hernández-Macedo, María Lucila; Padilha, Francine Ferreira

doi:10.1007/s11051-018-4387-z

Cited by 21 publications

(8 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PLGA is a commonly used synthetic polymer. Recently, it has been utilized as basic excipient for antibacterial polymeric nanoparticles production [127]. Clarithromycin antibiotic was successfully encapsulated within PLGA particles.…”

Section: Polymeric Nanoparticlesmentioning

confidence: 99%

Nanomedicine Fight against Antibacterial Resistance: An Overview of the Recent Pharmaceutical Innovations

et al. 2020

View full text Add to dashboard Cite

Based on the recent reports of World Health Organization, increased antibiotic resistance prevalence among bacteria represents the greatest challenge to human health. In addition, the poor solubility, stability, and side effects that lead to inefficiency of the current antibacterial therapy prompted the researchers to explore new innovative strategies to overcome such resilient microbes. Hence, novel antibiotic delivery systems are in high demand. Nanotechnology has attracted considerable interest due to their favored physicochemical properties, drug targeting efficiency, enhanced uptake, and biodistribution. The present review focuses on the recent applications of organic (liposomes, lipid-based nanoparticles, polymeric micelles, and polymeric nanoparticles), and inorganic (silver, silica, magnetic, zinc oxide (ZnO), cobalt, selenium, and cadmium) nanosystems in the domain of antibacterial delivery. We provide a concise description of the characteristics of each system that render it suitable as an antibacterial delivery agent. We also highlight the recent promising innovations used to overcome antibacterial resistance, including the use of lipid polymer nanoparticles, nonlamellar liquid crystalline nanoparticles, anti-microbial oligonucleotides, smart responsive materials, cationic peptides, and natural compounds. We further discuss the applications of antimicrobial photodynamic therapy, combination drug therapy, nano antibiotic strategy, and phage therapy, and their impact on evading antibacterial resistance. Finally, we report on the formulations that made their way towards clinical application.

show abstract

Section: Polymeric Nanoparticlesmentioning

confidence: 99%

Nanomedicine Fight against Antibacterial Resistance: An Overview of the Recent Pharmaceutical Innovations

et al. 2020

View full text Add to dashboard Cite

show abstract

“…However, encapsulation of glycopeptide antibiotics has often resulted in a loss of antimicrobial activity. [70][71][72] This is because, in the absence of any additional targeting or stimulus-responsive release mechanisms, drug release is slow and occurs over a long time, so the concentrations at the infection site may not reach the MIC. As we have seen, this problem may be circumvented by employing polymeric nanoparticles that are getting degraded by specific bacterial enzymes [75] or by functionalizing the nanoparticle surface with stimulus-responsive recognition elements such as aptamers that trigger the release of the cargo upon interaction with the bacterial surface.…”

Section: Discussionmentioning

confidence: 99%

“…For instance, vancomycin‐loaded PLGA nanoparticles with an average diameter of 239.3 ± 1.5 nm were synthesized by Gaspar et al via the double emulsification/solvent evaporation method. [ 70 ] However, when tested against S. aureus and MRSA, the nanoparticle‐encapsulated vancomycin had higher MIC values than free vancomycin (see Table 2), which may be due to the delayed drug release resulting in lower effective concentrations at short incubation times. Similar results were also obtained by Lotfipour et al, who synthesized vancomycin‐loaded PLGA nanoparticles 461 ± 33 nm in diameter.…”

Section: Nanoparticle‐based Formulations Of Vancomycinmentioning

confidence: 99%

Nanoparticle‐Based Formulations of Glycopeptide Antibiotics: A Means for Overcoming Vancomycin Resistance in Bacterial Pathogens?

Pothineni

Keller

2023

Advanced NanoBiomed Research

View full text Add to dashboard Cite

The occurrence and spreading of multidrug resistance in bacterial pathogens represent one of the greatest challenges of the 21st century. With fewer and fewer new antibiotics in development, novel and unconventional concepts in drug development and formulation need to be explored to overcome the global antibiotics crisis. Biomedical nanotechnology offers promising strategies for the reformulation of established antibiotics in such a way that they regain their activity against resistant pathogens. Herein, promising developments aimed at the synthesis of potent nanoparticle‐based formulations of glycopeptide antibiotics are reviewed. While glycopeptide antibiotics such as vancomycin and teicoplanin are widely used as drugs of last resort against Gram‐positive pathogens such as methicillin‐resistant Staphylococcus aureus (MRSA), bacterial resistance against these drugs is spreading. However, inhibiting cell wall synthesis via binding to cell wall precursor peptidoglycans, glycopeptide antibiotics exhibit a unique mode of action that renders them particularly promising candidates for nanoparticle‐based formulations with the ability to overcome glycopeptide antibiotic resistance. Herein, different formulation concepts based on multivalent presentation and encapsulation are introduced, different synthesis and conjugation strategies are discussed, and an attempt is made to rationalize their effects on the antibacterial activity of the resulting nanoparticle formulations.

show abstract

“…PLGA particle mediated immunotherapy represents a promising tool with diverse scope for potential applications. Targeted delivery of antibiotics loaded to PLGA particles has been described in several studies to effectively treat bacterial infections and reduce the risk of resistance development [ 149 , 150 , 151 ]. In a similar fashion, encapsulation and delivery of anti-viral and immunomodulating drugs have been successfully explored using PLGA particles to fight viral infections [ 152 , 153 , 154 , 155 ].…”

Section: Most Successful Application Of Plga Particles In Immunotherapymentioning

confidence: 99%

PLGA Particles in Immunotherapy

Horvath

Basler

2023

Pharmaceutics

View full text Add to dashboard Cite

Poly(lactic-co-glycolic acid) (PLGA) particles are a widely used and extensively studied drug delivery system. The favorable properties of PLGA such as good bioavailability, controlled release, and an excellent safety profile due to the biodegradable polymer backbone qualified PLGA particles for approval by the authorities for the application as a drug delivery platform in humas. In recent years, immunotherapy has been established as a potent treatment option for a variety of diseases. However, immunomodulating drugs rely on targeted delivery to specific immune cell subsets and are often rapidly eliminated from the system. Loading of PLGA particles with drugs for immunotherapy can protect the therapeutic compounds from premature degradation, direct the drug delivery to specific tissues or cells, and ensure sustained and controlled drug release. These properties present PLGA particles as an ideal platform for immunotherapy. Here, we review recent advances of particulate PLGA delivery systems in the application for immunotherapy in the fields of allergy, autoimmunity, infectious diseases, and cancer.

show abstract

Development and characterization of PLGA nanoparticles containing antibiotics

Cited by 21 publications

References 26 publications

Nanomedicine Fight against Antibacterial Resistance: An Overview of the Recent Pharmaceutical Innovations

Nanomedicine Fight against Antibacterial Resistance: An Overview of the Recent Pharmaceutical Innovations

Nanoparticle‐Based Formulations of Glycopeptide Antibiotics: A Means for Overcoming Vancomycin Resistance in Bacterial Pathogens?

PLGA Particles in Immunotherapy

Contact Info

Product

Resources

About